微卫星不稳定性与错配修复缺陷定义了一类以吸烟暴露、高肿瘤突变负荷及复发性体细胞MLH1失活为特征的肺癌亚群
研究采用两种经验证的生物信息学流程,从靶向二代测序数据分析5171例非小细胞肺癌(NSCLC)和315例小细胞肺癌(SCLC)患者的微卫星不稳定性(MSI)状态。MSI-H与错配修复缺陷(MMR-D)在NSCLC中检出21例(0.41%)、SCLC中检出6例(1.9%);MSI-H肺癌与吸烟、高肿瘤突变负荷及MLH1失活相关,部分晚期患者接受免疫检查点抑制剂(ICI)后获得持久临床获益。
要点
- NSCLC中MSI-H/MMR-D占0.41%,SCLC中占1.9%,均属少见亚群
- NSCLC的MSI-H病例全部有吸烟史,MSI-H与肿瘤突变负荷升高及MLH1双等位体细胞改变相关
- 晚期MSI-H肺癌接受ICI者中,NSCLC 8例中3例、SCLC 2例中2例获持久临床获益
核心结论
- MSI-H定义了一类少见的肺癌亚群,与吸烟、高肿瘤突变负荷及MLH1失活相关;部分患者对ICI有持久临床获益,但缓解范围较广,提示临床活性可能受共突变格局调控。
研究设计与样本
- 对5171例NSCLC和315例SCLC患者,采用两种经验证的生物信息学流程从靶向二代测序数据中分析MSI状态。
主要发现
- MSI-H与MMR-D在NSCLC中检出21例(0.41%),在SCLC中检出6例(1.9%)。
- NSCLC的MSI-H患者全部有吸烟史,包括11例腺癌。
- 与微卫星稳定病例相比,MSI-H与极高的肿瘤突变负荷相关(37.4 vs 8.5 muts/Mb,p < 0.0001)。
- 与微卫星稳定病例相比,MSI-H与MMR突变特征相关(43% vs 0%,p < 0.0001),并与MLH1体细胞双等位改变相关(52% vs 0%,p < 0.0001)。
- 免疫组化显示MLH1和PMS2表达缺失见于MLH1改变及野生型病例;多数MSI-H SCLC有MLH1失活证据,其中2例为MLH1启动子高甲基化。
关键数值与推荐
- MSI-H NSCLC中位肿瘤突变负荷为37.4 muts/Mb,微卫星稳定病例为8.5 muts/Mb(p < 0.0001)。
- MSI-H病例MMR突变特征比例为43%,微卫星稳定病例为0%(p < 0.0001)。
- MSI-H病例MLH1体细胞双等位改变比例为52%,微卫星稳定病例为0%(p < 0.0001)。
- 晚期MSI-H肺癌接受ICI治疗者中,NSCLC 8例中3例、SCLC 2例中2例获持久临床获益。
- NSCLC中STK11、KEAP1、JAK1在无应答者中突变、在应答者中为野生型。
临床怎么用
- 作者结论指出MSI-H定义了一类与吸烟、高肿瘤突变负荷及MLH1失活相关的少见肺癌亚群,部分患者对ICI有持久临床获益,但缓解范围较广,提示临床活性可能受共突变格局调控。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Microsatellite instability (MSI) and mismatch repair (MMR) deficiency represent a distinct oncogenic process and predict response to immune checkpoint inhibitors (ICIs). The clinicopathologic features of MSI-high (MSI-H) and MMR deficiency (MMR-D) in lung cancers remain poorly characterized. METHODS: MSI status from 5171 patients with NSCLC and 315 patients with SCLC was analyzed from targeted next-generation sequencing data using two validated bioinformatic pipelines. RESULTS: MSI-H and MMR-D were identified in 21 patients with NSCLC (0.41%) and six patients with SCLC (1.9%). Notably, all patients with NSCLC had a positive smoking history, including 11 adenocarcinomas. Compared with microsatellite stable cases, MSI-H was associated with exceptionally high tumor mutational burden (37.4 versus 8.5 muts/Mb, p < 0.0001), MMR mutational signatures (43% versus 0%, p < 0.0001), and somatic biallelic alterations in MLH1 (52% versus 0%, p < 0.0001). Loss of MLH1 and PMS2 expression by immunohistochemistry was found in MLH1 altered and wild-type cases. Similarly, the majority of patients with MSI-H SCLC had evidence of MLH1 inactivation, including two with MLH1 promoter hypermethylation. A single patient with NSCLC with a somatic MSH2 mutation had Lynch syndrome as confirmed by the presence of a germline MSH2 mutation. Among patients with advanced MSI-H lung cancers treated with ICIs, durable clinical benefit was observed in three of eight patients with NSCLC and two of two patients with SCLC. In NSCLC, STK11, KEAP1, and JAK1 were mutated in nonresponders but wild type in responders. CONCLUSIONS: We present a comprehensive clinicogenomic landscape of MSI-H lung cancers and reveal that MSI-H defines a rare subset of lung cancers associated with smoking, high tumor mutational burden, and MLH1 inactivation. Although durable clinical benefit to ICI was observed in some patients, the broad range of responses suggests that clinical activity may be modulated by co-mutational landscapes.
引用
- Yang SR, Gedvilaite E, Ptashkin R, et al. Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation. J Thorac Oncol. 2023. PMID: 37838086. doi:10.1016/j.jtho.2023.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。